-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 21, 2024

Examining Key Unmet Needs in Multiple Sclerosis

Author(s)Ryan Haumschild, PharmD, MS, MBA, Heidi Crayton, MD , Maria Lopes, MD

Key opinion leaders discuss the most significant unmet needs in the current treatment landscape for multiple sclerosis.

Episodes in this series

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"

EP. 2 Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"

EP. 3 Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

3 KOLs in this program

EP. 4 Examining Key Unmet Needs in Multiple Sclerosis

3 KOLs in this program

EP. 5 Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 6 MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

A panel of 3 experts on multiple sclerosis

EP. 7 Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 8 Examining Challenges with Drug Switching and Step Therapy in MS Treatment

A panel of 3 experts on multiple sclerosis

EP. 9 Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 10 BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 11 Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

A panel of 3 experts on multiple sclerosis

EP. 12 Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

A panel of 3 experts on multiple sclerosis

EP. 13 Multiple Sclerosis: Looking Toward the Future

What do you view as the biggest unmet needs in the current treatment landscape for MS?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Vitamin D3 | Image Credit: Adisak - stock.adobe.com

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

ByBrooke McCormick

August 6th 2026

Katherine Wilemon, CEO of the Family Heart Foundation

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

ByPearl Steinzor,Katherine Wilemon

August 6th 2026

Eosinophilic esophagitis | Image Credit: syahrir - stock.adobe.com

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

ByBrooke McCormick

August 6th 2026

Experts featured in this series.

Translating PFS Data for Patients: How Community Oncologists Communicate Trial Outcomes in RRFL

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

August 6th 2026

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

ByJulia Buchfuhrer, DO

August 6th 2026

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

AHA Proposes Staging System for Pediatric Cardiogenic Shock